BR112019001457A2 - tratamento e prevenção de distúrbios do sono - Google Patents

tratamento e prevenção de distúrbios do sono

Info

Publication number
BR112019001457A2
BR112019001457A2 BR112019001457-8A BR112019001457A BR112019001457A2 BR 112019001457 A2 BR112019001457 A2 BR 112019001457A2 BR 112019001457 A BR112019001457 A BR 112019001457A BR 112019001457 A2 BR112019001457 A2 BR 112019001457A2
Authority
BR
Brazil
Prior art keywords
treatment
prevention
sleep disorders
animal
compound
Prior art date
Application number
BR112019001457-8A
Other languages
English (en)
Portuguese (pt)
Inventor
Stephen C. Harris
Ram P. Kapil
Donald J. Kyle
Garth WHITESIDE
Original Assignee
Purdue Pharma L.P.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Purdue Pharma L.P. filed Critical Purdue Pharma L.P.
Publication of BR112019001457A2 publication Critical patent/BR112019001457A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M21/00—Other devices or methods to cause a change in the state of consciousness; Devices for producing or ending sleep by mechanical, optical, or acoustical means, e.g. for hypnosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Anesthesiology (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Acoustics & Sound (AREA)
  • Psychology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Physics & Mathematics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
BR112019001457-8A 2016-07-26 2017-07-25 tratamento e prevenção de distúrbios do sono BR112019001457A2 (pt)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201662366960P 2016-07-26 2016-07-26
US62/366,960 2016-07-26
US201762536097P 2017-07-24 2017-07-24
US62/536,097 2017-07-24
PCT/IB2017/054506 WO2018020418A1 (en) 2016-07-26 2017-07-25 Treatment and prevention of sleep disorders

Publications (1)

Publication Number Publication Date
BR112019001457A2 true BR112019001457A2 (pt) 2019-05-07

Family

ID=59714072

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112019001457-8A BR112019001457A2 (pt) 2016-07-26 2017-07-25 tratamento e prevenção de distúrbios do sono

Country Status (20)

Country Link
US (4) US10974081B2 (https=)
EP (1) EP3490563A1 (https=)
JP (2) JP7198197B2 (https=)
KR (2) KR102210209B1 (https=)
CN (1) CN109689058B (https=)
AU (2) AU2017304898B2 (https=)
BR (1) BR112019001457A2 (https=)
CA (1) CA3031388C (https=)
CL (1) CL2019000190A1 (https=)
EC (1) ECSP19014247A (https=)
IL (1) IL264294B (https=)
JO (1) JOP20190008A1 (https=)
MX (1) MX388469B (https=)
NZ (1) NZ750817A (https=)
PH (1) PH12019500177A1 (https=)
SG (1) SG11201900486WA (https=)
TN (1) TN2019000019A1 (https=)
TW (1) TWI661827B (https=)
WO (1) WO2018020418A1 (https=)
ZA (1) ZA201901055B (https=)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JOP20190008A1 (ar) 2016-07-26 2019-01-24 Purdue Pharma Lp علاج ومنع اضطرابات النوم
JP7108041B2 (ja) * 2018-01-24 2022-07-27 パーデュー、ファーマ、リミテッド、パートナーシップ 睡眠障害の治療及び予防
CA3097445A1 (en) * 2018-04-16 2019-10-24 Technologies Hop-Child, Inc. Systems and methods for the determination of arousal states, calibrated communication signals and monitoring arousal states
KR102198846B1 (ko) * 2018-06-29 2021-01-05 다인기술 주식회사 배뇨에 관한 설문을 수행하는 방법, 시스템 및 비일시성의 컴퓨터 판독 가능 기록 매체
US11547350B2 (en) 2018-12-26 2023-01-10 Industrial Technology Research Institute Personalized parameter learning method, sleep-aid device and non-transitory computer readable medium
CN111359074B (zh) * 2018-12-26 2022-08-02 财团法人工业技术研究院 个人化参数学习方法、睡眠辅助装置及存储介质
CN113301957A (zh) * 2019-01-31 2021-08-24 普渡制药公司 取代的喹喔啉型桥接哌啶化合物的多晶型形式
BR112022004576A2 (pt) * 2019-09-13 2022-06-14 Takeda Pharmaceuticals Co Métodos para diminuir ou tratar sonolência excessiva, tratar narcolepsia tipo 2 ou hipersonia idiopática, tratar distúrbio de trabalho de turno, aumentar latência de sono em manutenção de teste de insônia, melhorar classificação de escaça de sonolência de karolinska, diminuir ou melhorar sonolência subjetiva, aumentar insônia ou diminuir sonolência excessiva, melhorar classificação de escala de sonolência epworth, tratar narcolepsia tipo 2, diminuir ou tratar sonolência diurna excessiva, e, composição farmacêutica
CN114159568B (zh) * 2020-09-11 2025-08-01 北京原基华毅生物科技有限公司 Sik抑制剂在制备用于预防和/或治疗睡眠障碍的药物中的应用
MX2023013514A (es) 2021-05-21 2024-04-02 Purdue Pharma Lp Metodos para tratar la cistitis intersticial/sindrome de dolor en la vejiga.
TWI804037B (zh) 2021-11-02 2023-06-01 長庚醫療財團法人高雄長庚紀念醫院 生酮飲食之評估系統及其運作方法
KR20250026332A (ko) * 2022-06-24 2025-02-25 퍼듀 퍼머 엘피 과민성 방광 증후군의 치료 또는 예방 방법
WO2025085818A1 (en) 2023-10-19 2025-04-24 Purdue Pharma L.P. Sunobinop for use in method of treating alcohol use disorder

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3536809A (en) 1969-02-17 1970-10-27 Alza Corp Medication method
US3598123A (en) 1969-04-01 1971-08-10 Alza Corp Bandage for administering drugs
US3845770A (en) 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US3916899A (en) 1973-04-25 1975-11-04 Alza Corp Osmotic dispensing device with maximum and minimum sizes for the passageway
US4008719A (en) 1976-02-02 1977-02-22 Alza Corporation Osmotic system having laminar arrangement for programming delivery of active agent
IE58110B1 (en) 1984-10-30 1993-07-14 Elan Corp Plc Controlled release powder and process for its preparation
US5073543A (en) 1988-07-21 1991-12-17 G. D. Searle & Co. Controlled release formulations of trophic factors in ganglioside-lipsome vehicle
IT1229203B (it) 1989-03-22 1991-07-25 Bioresearch Spa Impiego di acido 5 metiltetraidrofolico, di acido 5 formiltetraidrofolico e dei loro sali farmaceuticamente accettabili per la preparazione di composizioni farmaceutiche in forma a rilascio controllato attive nella terapia dei disturbi mentali organici e composizioni farmaceutiche relative.
US5120548A (en) 1989-11-07 1992-06-09 Merck & Co., Inc. Swelling modulated polymeric drug delivery device
US5733566A (en) 1990-05-15 1998-03-31 Alkermes Controlled Therapeutics Inc. Ii Controlled release of antiparasitic agents in animals
US5698155A (en) 1991-05-31 1997-12-16 Gs Technologies, Inc. Method for the manufacture of pharmaceutical cellulose capsules
US5580578A (en) 1992-01-27 1996-12-03 Euro-Celtique, S.A. Controlled release formulations coated with aqueous dispersions of acrylic polymers
US5591767A (en) 1993-01-25 1997-01-07 Pharmetrix Corporation Liquid reservoir transdermal patch for the administration of ketorolac
IT1270594B (it) 1994-07-07 1997-05-07 Recordati Chem Pharm Composizione farmaceutica a rilascio controllato di moguisteina in sospensione liquida
ES2247604T3 (es) 1995-06-12 2006-03-01 G.D. SEARLE & CO. Composiciones que comprenden un inhibidor de ciclooxigenasa-2 y un inhibidor de 5-lipoxigenasa.
US6572891B1 (en) 1999-10-23 2003-06-03 Alkaloid Ad Sublingual oral dosage form
JP4056977B2 (ja) 2002-03-29 2008-03-05 田辺三菱製薬株式会社 睡眠障害治療薬
JP4739217B2 (ja) 2003-05-07 2011-08-03 サムヤン コーポレイション 速く溶ける錠剤を製造するための高可塑性顆粒
AR045939A1 (es) 2003-09-25 2005-11-16 Solvay Pharm Bv Derivados de bencimidazolona y quinazolinona como agonistas de los receptores orl 1 humanos
US7355045B2 (en) 2004-01-05 2008-04-08 Applera Corporation Isotopically enriched N-substituted piperazine acetic acids and methods for the preparation thereof
WO2006025267A1 (ja) * 2004-08-31 2006-03-09 Mitsubishi Pharma Corporation Per2タンパク質レベルの低下を作用機序とする睡眠障害治療薬
WO2008033024A2 (en) 2006-09-15 2008-03-20 Echo Pharmaceuticals B.V. Dosage unit for sublingual, buccal or oral administration of water-insoluble pharmaceutically active substances
MY150602A (en) * 2007-08-31 2014-01-30 Purdue Pharma Lp Subtituted-quinoxaline-type piperidine compounds and the uses thereof
TWI441658B (zh) 2008-03-11 2014-06-21 Takeda Pharmaceutical 口腔崩解固體製劑
KR101333660B1 (ko) * 2008-07-21 2013-11-27 시오노기세이야쿠가부시키가이샤 치환-퀴녹살린-형 가교-피페리딘 화합물 및 그의 용도
AU2012324015A1 (en) 2011-12-01 2013-06-20 Purdue Pharma L.P. Azetidine-substituted quinoxaline-type piperidine compounds and uses thererof
WO2014102592A2 (en) 2012-12-27 2014-07-03 Purdue Pharma L.P. Oxime/substituted quinoxaline-type piperidine compounds and uses thereof
US10118927B2 (en) * 2012-12-27 2018-11-06 Purdue Pharma L.P. Substituted piperidin-4-amino-type compounds and uses thereof
JOP20190008A1 (ar) 2016-07-26 2019-01-24 Purdue Pharma Lp علاج ومنع اضطرابات النوم

Also Published As

Publication number Publication date
PH12019500177A1 (en) 2019-10-14
CA3031388A1 (en) 2018-02-01
AU2017304898A1 (en) 2019-03-07
KR102210209B1 (ko) 2021-02-01
TW201817423A (zh) 2018-05-16
MX388469B (es) 2025-03-20
CL2019000190A1 (es) 2019-06-07
KR102531366B1 (ko) 2023-05-12
ZA201901055B (en) 2019-12-18
CN109689058A (zh) 2019-04-26
SG11201900486WA (en) 2019-02-27
WO2018020418A1 (en) 2018-02-01
AU2017304898B2 (en) 2020-08-20
US20190282836A1 (en) 2019-09-19
ECSP19014247A (es) 2019-05-31
US10974081B2 (en) 2021-04-13
JP7198197B2 (ja) 2022-12-28
NZ750817A (en) 2020-07-31
US11738023B2 (en) 2023-08-29
US20240058333A1 (en) 2024-02-22
AU2020273332B2 (en) 2022-11-24
CA3031388C (en) 2023-02-14
US20210330994A1 (en) 2021-10-28
TN2019000019A1 (en) 2020-07-15
KR20210013319A (ko) 2021-02-03
JP7291172B2 (ja) 2023-06-14
JP2021120379A (ja) 2021-08-19
AU2020273332A1 (en) 2020-12-17
US12370191B2 (en) 2025-07-29
MX2019001036A (es) 2019-06-10
IL264294A (en) 2019-02-28
IL264294B (en) 2022-06-01
TWI661827B (zh) 2019-06-11
US20260007660A1 (en) 2026-01-08
CN109689058B (zh) 2022-03-22
JP2019523269A (ja) 2019-08-22
KR20190029682A (ko) 2019-03-20
EP3490563A1 (en) 2019-06-05
JOP20190008A1 (ar) 2019-01-24

Similar Documents

Publication Publication Date Title
BR112019001457A2 (pt) tratamento e prevenção de distúrbios do sono
ZA202001717B (en) Compounds, salts thereof and methods for treatment of diseases
EP4497474A3 (en) Methods of treating rheumatic diseases using trimetazidine-based compounds
MX2021008281A (es) Estimuladores de guanilato ciclasa soluble (sgc).
MX391850B (es) Compuestos para usarse en el tratamiento o mejoramiento de la enfermedad de huntington
EA201591612A1 (ru) ПРИМЕНЕНИЕ ПИРАЗОЛПИРИМИДИНОВЫХ ПРОИЗВОДНЫХ ДЛЯ ЛЕЧЕНИЯ НАРУШЕНИЙ, СВЯЗАННЫХ С PI3Kδ
SG11201901061QA (en) Heterocyclic compound
MX376193B (es) Compuestos para tratar el cancer cerebral.
BR112015026297A2 (pt) terapia combinada composta por um inibidor tor quinase e um composto de 5-quinazolinona substituído para o tratamento de câncer
CL2017002242A1 (es) Método para tratar un tumor cerebral
MX2017017171A (es) Compuestos terapeuticos y composiciones para el tratamiento de trastornos sociales y trastornos de uso de sustancias.
MX368903B (es) Compuestos terapéuticos y sus usos en el tratamiento de enfermedades proliferativas.
MX2017015012A (es) Formulaciones tópicas y orales que comprenden taurina y magnesio para la prevención y el tratamiento del acné.
MX2020013297A (es) Compuestos para el tratamiento o la prevencion de enfermedades hepaticas.
EA035519B9 (ru) 1,3,4-тиадиазольные соединения и их применение в лечении рака
BR112021020962A2 (pt) Métodos de tratamento de prurido
MX2022006229A (es) Composiciones y metodos para el tratamiento de resistencia a la insulina.
AR114306A1 (es) Tratamiento y prevención de trastornos del sueño
BR112017021589A2 (pt) métodos para o tratamento de transtornos cardiovasculares
CL2021000743A1 (es) Métodos para tratar trastornos mieloproliferativos
BR112019004791A2 (pt) tratamento de esclerose múltipla com chs-131
MX2019000413A (es) Inhibidores de triptofano 2,3-dioxigenasa.
EA201891008A3 (ru) Лечение симптомов, связанных с андроген-депривационной терапией
WO2019040104A3 (en) COMPOUNDS, RELATED SALTS AND METHODS OF TREATING DISEASES
EA201990365A1 (ru) Лечение и предотвращение расстройств сна

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06W Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette]
B350 Update of information on the portal [chapter 15.35 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B12B Appeal against refusal [chapter 12.2 patent gazette]